BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paz M, Roberti J, Mos F, Cicora F. Conversion to Belatacept-Based Immunosuppression Therapy in Renal Transplant Patients. Transplantation Proceedings 2014;46:2987-90. [DOI: 10.1016/j.transproceed.2014.07.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Brakemeier S, Kannenkeril D, Dürr M, Braun T, Bachmann F, Schmidt D, Wiesener M, Budde K. Experience with belatacept rescue therapy in kidney transplant recipients. Transpl Int 2016;29:1184-95. [PMID: 27514317 DOI: 10.1111/tri.12822] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
2 Bamgbola O. Metabolic consequences of modern immunosuppressive agents in solid organ transplantation. Ther Adv Endocrinol Metab 2016;7:110-27. [PMID: 27293540 DOI: 10.1177/2042018816641580] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
3 Dürr M, Lachmann N, Zukunft B, Schmidt D, Budde K, Brakemeier S. Late Conversion to Belatacept After Kidney Transplantation: Outcome and Prognostic Factors. Transplantation Proceedings 2017;49:1747-1756.e1. [DOI: 10.1016/j.transproceed.2017.05.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
4 Badell IR, Karadkhele GM, Vasanth P, Farris AB, Robertson JM, Larsen CP. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation. Am J Transplant 2019;19:2342-9. [DOI: 10.1111/ajt.15319] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
5 Snyder HS, Duhart BT Jr, Krauss AG, Rao V. Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction. SAGE Open Med Case Rep 2016;4:2050313X16674865. [PMID: 27847589 DOI: 10.1177/2050313X16674865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 López-Oliva MO, Álvarez L, Testillano ML, Pérez T, Nieto MF, Santana MJ, González E, Herrero A, Selgas R, Jiménez C. Switch to belatacept in kidney graft recipients. Nefrologia 2017;37:550-2. [PMID: 28233569 DOI: 10.1016/j.nefro.2016.11.001] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Matz M, Fabritius K, Liu J, Lorkowski C, Brakemeier S, Unterwalder N, Dürr M, Mashreghi MF, Neumayer HH, Budde K. Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation. Transpl Immunol 2015;33:176-84. [PMID: 26478531 DOI: 10.1016/j.trim.2015.10.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]